Ihre E-Mail wurde erfolgreich gesendet. Bitte prüfen Sie Ihren Maileingang.

Leider ist ein Fehler beim E-Mail-Versand aufgetreten. Bitte versuchen Sie es erneut.

Vorgang fortführen?

Exportieren
  • 1
    In: IUBMB Life, Wiley, Vol. 72, No. 12 ( 2020-12), p. 2611-2626
    Kurzfassung: Idiopathic pulmonary fibrosis (IPF) is a progressive, life‐threatening lung disease with a poor prognosis. N‐acetyl‐seryl‐aspartyl‐lysyl‐proline (Ac‐SDKP) is a critical negative regulator of fibrosis development. However, it's extremely short half‐life greatly limits its applications. Previously, we reported an Ac‐SDKP analog peptide in which Asp and Lys residues were replaced with D‐amino acids (Ac‐SD D K D P). Ac‐SD D K D P exhibits better resistance to angiotensin‐1‐converting enzyme (ACE)‐mediated degradation and a longer half‐life than Ac‐SDKP in rat and human sera. The objective of this study was to explore the potential application of Ac‐SD D K D P for the treatment of IPF and to clarify the underlying mechanisms. We found that Ac‐SD D K D P exerted similar antifibrotic effects as Ac‐SDKP on human fetal lung fibroblast‐1 (HFL‐1) proliferation, α‐smooth muscle actin (α‐SMA), collagen I and collagen III expression, and Smad‐2 phosphorylation in vitro. In vivo, Ac‐SD D K D P exhibited significantly greater protective effects against bleomycin‐induced pulmonary fibrosis than Ac‐SDKP in mice. α‐SMA, CD45, collagen I and collagen III expression, and Smad‐2 phosphorylation were significantly decreased in the lungs of Ac‐SD D K D P‐treated but not Ac‐SDKP‐treated mice. Furthermore, a pull‐down experiment was used to screen for molecules that interact with Ac‐SDKP. Co‐immunoprecipitation (Co‐IP) and computer‐based molecular docking experiments demonstrated an interaction between Ac‐SDKP or Ac‐SD D K D P (Ac‐SDKP/Ac‐SD D K D P) and serine/arginine‐rich protein‐specific kinase 1 (SRPK1) that caused inhibition SRPK1‐mediated phosphatidylinositol‐3 kinase/ serine/threonine kinase (PIK3/AKT) signaling pathway activation and Smad2 phosphorylation and thereby attenuated lung fibrosis. Our data suggest that long‐acting Ac‐SD D K D P may potentially be an effective drug for the treatment of pulmonary fibrosis. The interacting molecule and antifibrotic mechanism of Ac‐SDKP/Ac‐SD D K D P were also identified, providing an experimental and theoretical foundation for the clinical application of the drug.
    Materialart: Online-Ressource
    ISSN: 1521-6543 , 1521-6551
    URL: Issue
    Sprache: Englisch
    Verlag: Wiley
    Publikationsdatum: 2020
    ZDB Id: 2009952-6
    ZDB Id: 2485214-4
    SSG: 12
    Bibliothek Standort Signatur Band/Heft/Jahr Verfügbarkeit
    BibTip Andere fanden auch interessant ...
Schließen ⊗
Diese Webseite nutzt Cookies und das Analyse-Tool Matomo. Weitere Informationen finden Sie auf den KOBV Seiten zum Datenschutz